Compare Abeona Therapeutics Inc (ABEO) vs Check Point Software Technologies Ltd (CHKP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Check Point Software Technologies Ltd — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Check Point Software Technologies Ltd trades at $136.86 (market cap $14.43B). The key difference: Check Point Software Technologies Ltd is far larger — about 38.7× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Check Point Software Technologies Ltd nearer its low. Which is the better fit depends on your goals.
| ABEO | CHKP | |
|---|---|---|
Market Cap | $373.32M | $14.43B |
Sector | Health | Technology |
52-Week High | $7.23 | $231.23 |
52-Week Low | $4.17 | $112.47 |
Enterprise Value | $228.22M | $13.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
CHKP trades at $138.87, up 1.68% today, with a bullish technical outlook supported by moving averages and strong support at $136. The company demonstrates robust fundamentals with a 38.37% net income margin, consistent earnings beats, and strategic AI partnerships enhancing its cybersecurity offerings. Recent news highlights ESG reporting and cloud security expansions.
Outlook remains positive with a consensus price target of $148.73, though risks include insider sales and legal investigations. The stock offers growth potential from AI integration but faces competitive and regulatory headwinds that warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →
